14 matches for your search in the start-up spotlight
rss
YUMAB is a privately-held German biotechnology company that provides tailored solutions for your human antibody development and antibody engineering problems. We provide rapid, large-scale discovery and optimization of human monoclonal antibodies, custom libraries, antibody engineering (e.g., ...
MagBio Genomics develops and commercializes magnetic bead-based products for nucleic acid isolation including biomarkers as tools for liquid biopsy genomic research. Our current focus encompasses products that allow both safeguarding integrity of bio-samples and efficient isolation of ...
Reveal Biosciences is a computational pathology company combining traditional histopathology with artificial intelligence to transform tissue biology into actionable data. Our technology pipeline includes a high-plex multiplex platform and machine learning computational pathology solutions to ...
uBiome is a citizen science startup that sequences the human microbiome. As the first and largest successful crowdsourced citizen science project in history, we allow the public access to cutting edge sequencing technology and are building a data platform to gather, analyze, and translate data ...
At Transcriptic, our mission is to turn biology into an information technology, driven by data, computation, and high-throughput robotics with the goal of substantially advancing drug discovery. Our team brings together deep expertise in biology, automation, and software engineering to set new ...
Memo Therapeutics AG (”MTx”) is a late-stage biotech company developing best-in-class therapeutic antibodies to transform the lives of patients with virus infections and cancer. MTx’ lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney ...
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases ...
